İmmün Kontrol Noktası İnhibitörleri ile Tedavi Edilen Malign Melanom Hastalarında Antibiyotik ve Kortikosteroid Kullanımının Tedaviye Etkileri
Amaç: Son yıllarda malign melanom tedavisi tamamen değişmiş, özellikle immün kontrol noktası inhibitörlerinin kullanıma girmesiyle yaşam süresi belirgin olarak uzamıştır. Ancak bu ilaçlar hastaların sadece bir kısmında etkili olabilmektedir. Bu tedavilerden fayda gören hastaların belirlenebilmesi için biyobelirteçler ve tedaviye etki eden faktörler araştırılmaktadır. Çalışmamızda immün kontrol noktası inhibitörü kullanan ileri evre malign melanom hastalarında antibiyotik ve kortikosteroid kullanımının ve hastaların melanom için daha önce adjuvant olarak aldıkları tedavilerin tedavi sonuçları üzerine etkilerini araştırdık. Gereç ve Yöntemler: Çalışmamızda immün kontrol noktası inhibitörleri ile tedavi edilen ileri evre malign melanom hastaları retrospektif olarak tarandı. Yirmidokuz hastanın verilerine ulaşıldı. Hastane kayıtlarından antibiyotik ve kortikosteroid kullanımı ve hastaların daha önce aldıkları adjuvant tedavi verilerine ulaşılarak sağkalım analizleri yapıldı. Bulgular: Yirmidokuz hastanın 18 i %62 antibiyotik kullanımıştı, 16 sında %55 herhangi bir sebeple sistemik kortikosteroid kullanımı vardı. 17 %58,6 hastada adjuvant interferon kullanılmıştı. İstatistiki anlamlılığa ulaşmamasına rağmen tedavi sırasında antibiyotik kullananlarda progresyonsuz sağ kalım PFS ve genel sağ kalım OS daha kısaydı. PFS 9 ay ile 15,9 ay, p= 0,561, OS 18 ay ile 38 ay, p=0,404 . Progresyonsuz sağ kalım ve OS immün kontrol noktası inhibitörleri ile beraber kortikosteroid kullananlarda daha kısaydı PFS 27,2 ay ile 5,4 ay, p=0,007, OS 50 ay ile 14 ay, p=0,009 . Adjuvant dönemde interferon kullanmış olan hastaların metastatik evrede immün kontrol noktası inhibitörleri ile hem pfs hem os sürelerinin daha uzun olduğu görüldü PFS 23,2 ay ile 6.2 ay, p=0,019, OS 39,8 ay ile 12,9 ay, p=0,004 .Sonuç: İleri evre metastatik malign melanom hastalarında immün kontrol noktası inhibitörleri ile beraber antibiyotik ve kortikosteroid kullanımı tedavi sonuçlarını olumsuz etkileyebilmektedir
Impact of Antibiotics and Corticosteroids on The Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
Objective: The treatment of malignant melanoma has changed a lot in recent years. The use of immune checkpoint inhibitors has prolonged survival in patients with advanced melanoma. Our study evaluates the impact of antibiotics, corticosteroids, and adjuvant treatment on the efficacy of immune checkpoint inhibitors in patients with advanced melanoma.Material and Methods: We conducted a retrospective analysis of metastatic melanoma patients treated with ipilimumab and nivolumab. Concomitant antibiotics, corticosteroids for any reason, and prior adjuvant treatment for melanoma were recorded. Progression free survival and overall survival were compared in each group. Results: We enrolled 29 patients with advanced melanoma treated with immune checkpoint inhibitors. Eighteen 62.1% patients had concomitant antibiotic therapy, and 16 55.2% patients had used corticosteroids for any reason. Seventeen patients 58.6% had adjuvant therapy with interferon alpha.Although not significant, PFS and OS were shorter in patients treated with concomitant antibiotics: PFS 15.9 months vs. 9 months, p=0.561; OS 38 months vs. 18 months, p=0.404.PFS and OS were shorter in patients who had used corticosteroids during immune checkpoint inhibitor treatment: PFS 27.2 months vs. 5.4 months p=0.007 and OS 50 months vs. 14 months p=0.009 . PFS was 23.2 months in the adjuvant interferon group vs. 6.2 months with no prior interferon, p=0.019. Overall survival was also longer in patients with prior adjuvant interferon treatment: 39.8 months vs. 12.9 months p=0.004 .Conclusion: Concomitant use of antibiotics and corticosteroids in patients with advanced melanoma may affect the efficacy of immune checkpoint inhibitors
___
- 1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman
JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D,
Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J,
Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier
CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD,
Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba
WJ. Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med 2010; 363(8):711-23.
- 2. Robert C, Schachter J, Long GV, Arance A, Grob JJ,
Mortier L, Daud A, Carlino MS, McNeil C, Lotem
M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O,
Mateus C, Shapira-Frommer R, Kosh M, Zhou H,
Ibrahim N, Ebbinghaus S, Ribas A. KEYNOTE-006
investigators. Pembrolizumab versus ipilimumab in
advanced melanoma. N Engl J Med 2015; 372(26):2521-
32.
- 3. Robert C, Long GV, Brady B, Dutriaux C, Maio M,
Mortier L, Hassel JC, Rutkowski P, McNeil C, KalinkaWarzocha E, Savage KJ, Hernberg MM, Lebbé C,
Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C,
Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas
H, Lundgren-Eriksson L, Horak C, Sharkey B,Waxman
IM, Atkinson V, Ascierto PA. Nivolumab in previously
untreated melanoma without BRAF mutation. N Engl J
Med 2015; 372(4):320-30.
- 4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey
CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino
MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur
GA, Ascierto PA, Long GV, Callahan MK, Postow MA,
Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A,
Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined
Nivolumab and ipilimumab or monotherapy in untreated
melanoma. N Engl J Med 2015; 373(1):23-34.
- 5. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R,
Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ,
Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther
PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet
C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P,
Yessaad N, Vivier E, Ryffel B, lson CO, Doré J, Kroemer
G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L.
The intestinal microbiota modulates the anticancer
immune effects of cyclophosphamide. Science 2013;
342(6161):971-6.
- 6. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre
ML, Luke JJ, Gajewski TF. The commensal microbiome is
associated with anti-PD-1 efficacy in metastatic melanoma
patients. Science 2018; 359(6371):104-8.
- 7. Sivan A, Corrales L, Hubert N, Williams JB, AquinoMichaels K, Earley ZM, Benyamin FW, Lei YM, Jabri
B, Alegre ML, Chang EB, Gajewski TF. Commensal
bifidobacterium promotes antitumor immunity
and facilitates anti-PD-L1 efficacy. Science 2015;
350(6264):1084-9.
- 8. Francino MP. Antibiotics and the human gut microbiome:
Dysbioses and accumulation of resistances. Front
Microbiol 2016; 6:1543.
- 9. Derosa L, Routy B, Enot D, Baciarello G, Massard C,
Loriot Y, Fizazi K, Escudier BJ, Zitvogel L, Albiges
L. Impact of antibiotics on outcome in patients with
metastatic renal cell carcinoma treated with immune
checkpoint inhibitors. Journal of Clinical Oncology 2017;
(suppl 6):462.
- 10. Derosa L, Hellmann MD, Spaziano M, Halpenny D,
Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC,
Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L,
Escudier B, Routy B. Negative association of antibiotics
on clinical activity of immune checkpoint inhibitors in
patients with advanced renal cell and non-small-cell lung
cancer. Ann Oncol 2018; 29(6):1437-44.
- 11. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou
MT, Daillère R, Fluckiger A, Messaoudene M, Rauber
C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V,
Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot
N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip
JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi
H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B,
Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot
Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier
B, Hellmann MD, Eggermont A, Raoult D, Albiges L,
Kroemer G, Zitvogel L. Gut microbiome influences
efficacy of PD-1-based immunotherapy against epithelial
tumors. Science 2018; 359(6371):91-7.
- 12. Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher
P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R,
Ghiringhelli F. Antibiotic use does not appear to influence
response to nivolumab. Anticancer Res 2017; 37(6):3195-
200.
- 13. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA,
Callahan MK, Carvajal RD, Dickson MA, D’Angelo
SP, Woo KM, Panageas KS, Wolchok JD, Chapman
PB. Immune-related adverse events, need for systemic
immunosuppression, and effects on survival and time to
treatment failure in patients with melanoma treated with
ipilimumab at memorial sloan kettering cancer center. J
Clin Oncol 2015; 33(28):3193-8.
- 14. Garant A, Guilbault C, Ekmekjian T, Greenwald Z,
Murgoi P, Vuong T. Concomitant use of corticosteroids
and immune checkpoint inhibitors in patients with
hematologic or solid neoplasms: A systematic review. Crit
Rev Oncol Hematol 2017; 120:86-92.
- 15. Arbour KC, Mezquita L, Long N, Rizvi H, Auclin
E, Ni A, Bernal GM, Chaft JE, Ferrara R, Lai WCV,
Hendriks L, Sabari JK, Caramella C, Plodkowski AJ,
Halpenny D, Planchard D, Riely GJ, Besse B, Hellmann
MD. Deleterious effect of baseline steroids on efficacy of
PD-(L) 1 blockade in patients with NSCLC. J Clin Oncol
2018; (Suppl 15): 9003.
- 16. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry
RM, Royal RE, Kammula US, Hughes MS, Allen TE,
Levy CL, Yellin M, Nichol G, White DE, Steinberg
SM, Rosenberg SA. Prognostic factors related to clinical
response in patients with metastatic melanoma treated
by CTL-associated antigen-4 blockade. Clin Cancer Res
2007; 13:6681-8.
- 17. Rafique I, Kirkwood JM, Tarhini AA. Immune checkpoint
blockade and interferon-α in melanoma. Semin Oncol
2015; 42(3):436-47.
- 18. Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF.
Cutting edge: IL-12 and type I IFN differentially program
CD8 T cells for programmed death 1 re-expression levels
and tumor control. J Immunol 2013;191(3):1011-5.